Roland Turck

Roland Turck is a Scientific Advisor at Virtuleap and Managing Partner at TurckBio. Roland has over 7 years of experience helping small and large companies develop and commercialize their specialty medicine assets. Roland is focused on oncology, rare diseases, CNS, and ophthalmology. Roland has also served as a non-executive director at Vicus Therapeutics and as an advisory board member at AppNovation. In addition, they are a member of the ESMO Annals of Oncology Editorial Board (2017-2018). Some of their recent work includes technology assessment for US and EU investors, senior adviser to the Board of Actinium Pharmaceuticals (NYSE: ATNM), revised development plan for a private oncology company, designed development strategy for an early stage oncology company, opportunity assessment for Private Equity fund, and helped securing series A and B funding for a medical device start-up.

Roland Turck was educated at the University of Bonn, the Faculte de Medicine Rene Decartes, CH St. Anne, Northwestern University, and the University of Cape Town. Roland received their Abitur from Friedrich-Ebert-Gymnasium, Bonn in 1983.

Roland Turck works with the scientific advisory team.